Company

A medical device company born in a hospital corridor.

Rethink Medical was created around a simple observation: some of the most widely used devices in healthcare are also the least questioned. T-Control® is our answer to one of them.

Mission

Rethinking what is taken for granted

We develop medical devices around patient experience, healthcare-professional needs and responsible use of healthcare resources. Our work starts with real clinical practice, not with technology looking for a problem.

T-Control® is an indwelling urinary catheter with an integrated flow-control valve designed to support controlled urinary drainage and simplify catheter management.

Clinical origin

Founded and led by professionals with hands-on nursing and clinical experience.

European roots

Based in the Canary Islands, Spain, operating across the European Union.

Quality management

Quality management system assessed under the MDR conformity assessment process for T-Control®.

Public backing

Supported by CDTI, SODECAN, ENISA, EIT Health and Horizon Europe programmes.

Trajectory

Milestones

  1. 2026

    T-Control® reaches the market

    Commercial launch of the CE-marked T-Control® urinary catheter begins.

  2. 2026

    International commercialisation begins

    First international distribution agreement signed for T-Control®.

  3. 2025

    EAUN Scientific Research Award

    First Scientific Research Prize at the European Association of Urology Nurses Congress.

  4. 2025

    CE Marking under EU MDR

    T-Control® obtained CE marking as a Class IIb medical device under Regulation (EU) 2017/745.

  5. 2024

    Forbes Spain recognition

    Rethink Medical founder Manuel Luque selected among Forbes Spain’s “24 Changemakers 2024”.

  6. 2024

    Top 100 Startups in Spain

    Selected by APTE.

  7. 2023

    Canarias Destino Startup winner

    Winner of the first edition of the programme.

  8. 2023

    Clinical study begins

    First patients enrolled in a clinical study of T-Control®.

  9. 2023

    Scientific evidence published

    First peer-reviewed studies evaluating the usability and potential benefits of T-Control® published in the International Journal of Urological Nursing.

  10. 2022

    EIC Accelerator Seal of Excellence

    Rethink Medical received a further Seal of Excellence under the EIC Accelerator, bringing the total number of European Commission Seals of Excellence received to four.

  11. 2021

    EIT Health InnoStars finalist

    Recognition of T-Control® within the European health innovation ecosystem.

  12. 2019–2020

    Three Horizon 2020 Seals of Excellence

    T-Control® received three Seals of Excellence from the European Commission following highly competitive Horizon 2020 SME Instrument evaluations. The proposals passed the European Commission assessment thresholds for excellence, impact, and quality and efficiency of implementation.

  13. 2019

    Entrepreneurship recognition

    Entrepreneur Award by Fundación MAPFRE Guanarteme.

  14. 2017

    European Commission support

    Selected under the SME Instrument Phase I programme.

  15. 2016

    EIT Health Headstart

    Selected for the EIT Health Headstart Programme.

  16. 2014

    Rethink Medical is founded

    Created in the Canary Islands to rethink urinary catheterisation through clinician-led innovation.

  17. 2012

    The journey begins

    First patent priority covering the core technology behind T-Control®.